TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27240885

Group type: EXPERIMENTAL
Intervention: Targeted treatments for differentiated and medullary thyroid cancers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (surgery followed by either radioactive iodine or observation)
Number of subjects: 0
Study: 27241455

Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Number of subjects: 5
Study: 27242464

Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (CSR) for 7 days (4 hours time in bed, TIB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (CSR) for 7 days (4 hours TIB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery days (8 hours TIB) after CSR
Number of subjects: 12
Study: 27242521

Group type: EXPERIMENTAL
Intervention: Amnestic mild cognitive impairment (aMCI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cognitively normal control (NC)
Number of subjects: 44
Study: 27242930

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-i)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Auricular Acupuncture (AA)
Number of subjects: 59
Study: 27243356

Group type: EXPERIMENTAL
Intervention: Hydrogel daily disposable contact lenses (1-DAY ACUVUE MOIST)
Number of subjects: 86
Study: 27244371

Group type: COMPARATOR
Intervention: Single BVS
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Multiple BVS
Number of subjects: 236
Study: 27244805

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulator therapy
Number of subjects: 1
Study: 27244849

Group type: EXPERIMENTAL
Intervention: Infants of mothers with insulin use before pregnancy (IBP)
Number of subjects: 10781

Group type: COMPARATOR
Intervention: Infants of mothers without IDDM
Number of subjects: 10781
Study: 27244882

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (100 mg/m2) on day 1, 8, 22 and 29, and cisplatin (75 mg/m2) on day 1 and 22
Number of subjects: 35
Study: 27245095

Group type: EXPERIMENTAL
Intervention: Panobinostat (HDAC inhibitor)
Number of subjects: 1
Study: 27245295

Group type: EXPERIMENTAL
Intervention: Maternal Antiretroviral Therapy (ART)
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 2387
Study: 27245312

Group type: EXPERIMENTAL
Intervention: AG-120 (mutant IDH1 inhibitor)
Number of subjects: 3
Study: 27245618

Group type: EXPERIMENTAL
Intervention: Executive Reaction Time (RT) test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhibitory control assessment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Attention assessment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)
Number of subjects: 16
Study: 27245663

Group type: EXPERIMENTAL
Intervention: GPR101 duplication
Number of subjects: 153
Study: 27245762

Group type: EXPERIMENTAL
Intervention: Modified Italian EPIC Food Frequency Questionnaire (FFQ)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 7-day weighed food record
Number of subjects: 200
Study: 27245833

Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 107

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 107
Study: 27246166

Group type: EXPERIMENTAL
Intervention: Palliative care services provided in 30 centres across 12 countries, including 24 hospitals, 4 hospices, 1 nursing home, and 1 home-care service.
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Patients' self-reported symptoms collected at baseline and monthly thereafter.
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Follow-up data on patient mortality.
Number of subjects: 1698
Study: 27246604

Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 117

Group type: COMPARATOR
Intervention: HCV mono-infection
Number of subjects: 117
Study: 27246911

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 23
Study: 27247136

Group type: EXPERIMENTAL
Intervention: Idelalisib monotherapy for 2 months followed by 6 months of combination therapy with idelalisib and ofatumumab
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Idelalisib reinitiated with steroids
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Idelalisib therapy
Number of subjects: 24
Study: 27247202

Group type: EXPERIMENTAL
Intervention: Oral tablets
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vaginal gel
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Injectable, implant, or vaginal ring
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vaginal film or suppository
Number of subjects: 68
Study: 27247324

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 1144
Study: 27249077

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27249553

Group type: EXPERIMENTAL
Intervention: PTT-CEUS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PTT-DCE-MRI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nPTT-CEUS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PTT-CEUS and nPTT-CEUS
Number of subjects: 20
Study: 27249939

Group type: EXPERIMENTAL
Intervention: Constant rate of force application with varying peak force conditions.
Number of subjects: 25
Study: 27251684

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 112

Group type: COMPARATOR
Intervention: Metabolic syndrome (MetS)
Number of subjects: 112
Study: 27251869

Group type: EXPERIMENTAL
Intervention: Direct outreach (DO) recruitment approach
Number of subjects: 19354
Study: 27251870

Group type: EXPERIMENTAL
Intervention: Provider-based recruitment
Number of subjects: 3371

Group type: COMPARATOR
Intervention: Household-based recruitment
Number of subjects: 3371
Study: 27251871

Group type: EXPERIMENTAL
Intervention: Provider-based sampling (PBS)
Number of subjects: 850
Study: 27251872

Group type: EXPERIMENTAL
Intervention: Direct outreach strategies (direct mail, mass media, provider referrals, social networking)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Outreach strategies
Number of subjects: 10

Group type: COMPARATOR
Intervention: Community characteristics
Number of subjects: 10
Study: 27252072

Group type: EXPERIMENTAL
Intervention: Internet campaign (online quiz competition)
Number of subjects: 6720

Group type: COMPARATOR
Intervention: Promotional leaflets (control group)
Number of subjects: 6720
Study: 27252174

Group type: EXPERIMENTAL
Intervention: Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: External control
Number of subjects: 45
Study: 27252647

Group type: EXPERIMENTAL
Intervention: GLP-1 analog liraglutide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27252787

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 279
Study: 27253664

Group type: EXPERIMENTAL
Intervention: Proteasomal inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type AIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AIP variants
Number of subjects: 0
Study: 27253988

Group type: EXPERIMENTAL
Intervention: ILIT with MAT-Feld1 adsorbed to aluminum hydroxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aluminum hydroxide (placebo)
Number of subjects: 20
Study: 27255328

Group type: EXPERIMENTAL
Intervention: Insulin treatment in East Asian patients with T2D
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Noninsulin anti-hyperglycemic agents usage
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Basal insulin usage
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (DDS)
Number of subjects: 671
Study: 27255499

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 20
Study: 27255678

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg (dose level 1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg (dose level 2)
Number of subjects: 9
Study: 27255774

Group type: EXPERIMENTAL
Intervention: Intramyocardial implantation of stromal vascular fraction (SVF)
Number of subjects: 28
Study: 27256085

Group type: EXPERIMENTAL
Intervention: RSV-attributable GP episodes
Number of subjects: 450158

Group type: EXPERIMENTAL
Intervention: RSV-attributable hospitalisations
Number of subjects: 450158

Group type: EXPERIMENTAL
Intervention: RSV-attributable deaths
Number of subjects: 450158

Group type: EXPERIMENTAL
Intervention: RSV-attributable GP episodes for otitis media
Number of subjects: 450158

Group type: EXPERIMENTAL
Intervention: RSV-attributable antibiotic prescriptions
Number of subjects: 450158

Group type: COMPARATOR
Intervention: Comparison with influenza
Number of subjects: 450158
Study: 27256597

Group type: EXPERIMENTAL
Intervention: Audiovisual biofeedback (AV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Free breathing (FB)
Number of subjects: 10
Study: 27256670

Group type: EXPERIMENTAL
Intervention: SB623 (modified bone marrow-derived mesenchymal stem cells)
Number of subjects: 18
Study: 27256708

Group type: EXPERIMENTAL
Intervention: Height adjustable desk intervention for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitting posture
Number of subjects: 0
Study: 27256874

Group type: EXPERIMENTAL
Intervention: Lenalidomide and Sorafenib (sorafenib 400 mg p.o. b.i.d. and lenalidomide 15 mg p.o. daily, with planned dose escalation)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lenalidomide and Sorafenib
Number of subjects: 5
Study: 27257978

Group type: EXPERIMENTAL
Intervention: REP 2055 monotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: REP 2139-Ca monotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined treatment with pegylated interferon alpha 2a or thymosin alpha 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up after REP 102 study
Number of subjects: 20
Study: 27258098

Group type: EXPERIMENTAL
Intervention: Red blood cells from obese participants with metabolic abnormalities (OMA+)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Postprandial period after high-fat meal
Number of subjects: 9
Study: 27258399

Group type: EXPERIMENTAL
Intervention: Hybrid mobile testing (2-week multidisease community health campaign followed by home-based testing)
Number of subjects: 116326

Group type: EXPERIMENTAL
Intervention: Hybrid mobile testing
Number of subjects: 116326
Study: 27258476

Group type: EXPERIMENTAL
Intervention: activ C disc prosthesis
Number of subjects: 200
Study: 27258647

Group type: EXPERIMENTAL
Intervention: PCV13 (two doses, eight weeks apart)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PPSV23 (one dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 100
Study: 27259804

Group type: EXPERIMENTAL
Intervention: High frequency of vegetables intake
Number of subjects: 1903

Group type: COMPARATOR
Intervention: Low frequency of vegetables intake
Number of subjects: 1903
Study: 27260009

Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (HRV; Rotarix™, GSK Vaccines)
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1348
Study: 27260636

Group type: EXPERIMENTAL
Intervention: 40% L-menthol applied simultaneously with 10% CA
Number of subjects: 14

Group type: COMPARATOR
Intervention: 10% CA alone
Number of subjects: 14
Study: 27261237

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1 inhibitor concentrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ecallantide
Number of subjects: 0
Study: 27261467

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg orally once daily three times per week
Number of subjects: 15
Study: 27261549

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27262736

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early uNGAL excretion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Post-operative outcome
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Increase in serum creatinine >50%
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oliguria (urine output <0.5 ml kg(-1) h(-1))
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 200
Study: 27262861

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Metallic everolimus-eluting stent (EES)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Post-procedural asymmetry index (AI) >0.30
Number of subjects: 470
Study: 27265450

Group type: EXPERIMENTAL
Intervention: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 242
Study: 27266507

Group type: EXPERIMENTAL
Intervention: Augmentation index
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Stroke volume
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Systemic vascular resistance
Number of subjects: 488
Study: 27266697

Group type: EXPERIMENTAL
Intervention: Albendazole treatment (400 mg administered once every 3 months for 12 months)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo treatment (administered once every 3 months for 12 months)
Number of subjects: 700
Study: 27266702

Group type: EXPERIMENTAL
Intervention: Panax ginseng and salvia miltiorrhiza supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27266721

Group type: EXPERIMENTAL
Intervention: Tac-OD dosing based on CYP3A5 genotypes: 0.20 mg/kg/day for CYP3A5*3/*3, 0.25 mg/kg/day for CYP3A5*3/*3, 0.30 mg/kg/day for CYP3A5*1/*3, 0.35 mg/kg/day for CYP3A5*1/*1.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tac-OD dosing based on CYP3A5 genotypes.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Simplified Tac-OD strategy.
Number of subjects: 151
Study: 27267105

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM + LoDEX)
Number of subjects: 3
Study: 27267107

Group type: EXPERIMENTAL
Intervention: cf-PWV determined using the SphygmoCor System
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CAVI estimated using VASERA
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: telomere length
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: carotid intima-media thickness
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: central and peripheral augmentation index
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ankle-brachial pulse wave velocity
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ankle-brachial index
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: retinal arteriovenous index
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: renal and cardiac organ damage
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: lifestyles (physical activity, adherence to the Mediterranean diet, alcohol and tobacco consumption)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: psychological factors (depression, anxiety and chronic stress)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: inflammatory factors and oxidative stress
Number of subjects: 500
Study: 27267182

Group type: COMPARATOR
Intervention: Conventional treatment group (Group A) with physical, occupational, speech-language or other conventional rehabilitation therapies.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination treatment group (Group B) with traditional Korean medicine interventions (herbal medicine, chuna, moxibustion, and acupuncture) in addition to conventional treatment.
Number of subjects: 300
Study: 27267254

Group type: EXPERIMENTAL
Intervention: Ibrutinib (140 mg, single oral dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control (n=6)
Number of subjects: 40
Study: 27267549

Group type: EXPERIMENTAL
Intervention: Uncomplicated acute appendicitis
Number of subjects: 705

Group type: COMPARATOR
Intervention: Complicated acute appendicitis (CA2)
Number of subjects: 705
Study: 27267608

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks until progression
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 36
Study: 27267887

Group type: EXPERIMENTAL
Intervention: Training and support for Screening and Brief Interventions (SBI)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Financial reimbursement
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Internet-based method of delivering advice on SBI
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Implementation strategies for SBI
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Frequent exposure of SBI in media and guidelines
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: SBI facilitating information systems and protocol-led care
Number of subjects: 68
Study: 27267942

Group type: EXPERIMENTAL
Intervention: Capillary lactate measurement on admission
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Capillary lactate measurement
Number of subjects: 120
Study: 27268271

Group type: EXPERIMENTAL
Intervention: Axial Length (AL)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Anterior Chamber Depth (ACD)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Anterior Chamber Volume (ACV)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Spherical Equivalent
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Accommodation
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Contrast Sensitivity (AULCSF)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Refractive Correction Change
Number of subjects: 218
Study: 27268471

Group type: EXPERIMENTAL
Intervention: Walking activities
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nonwalking activities
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Short walks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overall physical activity
Number of subjects: 42
Study: 27268499

Group type: EXPERIMENTAL
Intervention: Modified Mallampati classification
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Upper lip bite test
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Mouth opening
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Height to thyromental distance (HT/TMD)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Neck circumference to thyromental distance (NC/TMD)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: LEMON model
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Naguib model
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: POGO score
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Overall predictive airway assessment tests
Number of subjects: 243
Study: 27269295

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg every 4 weeks for 4 months (2 mg/kg for those ≤40 kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Canakinumab reintroduced on relapse, administered every 4 weeks (increased to every 8 weeks) for 24 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment
Number of subjects: 20
Study: 27269940

Group type: EXPERIMENTAL
Intervention: MART1-specific CTLs followed by anti-CTLA-4 (ipilimumab)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ipilimumab monotherapy
Number of subjects: 10
Study: 27269945

Group type: EXPERIMENTAL
Intervention: Neutropenic diet and social restrictions (food, social contacts, pets)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Age, weight group, risk stratification, and nonabsorbable antibiotics
Number of subjects: 339
Study: 27269947

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 or 3 mg/kg every 2 weeks)
Number of subjects: 81
Study: 27270171

Group type: EXPERIMENTAL
Intervention: Centripetal lesions with persistent phase rim
Number of subjects: 17

Group type: COMPARATOR
Intervention: Centripetal lesions with transient phase rim
Number of subjects: 17

Group type: COMPARATOR
Intervention: Centrifugal lesions
Number of subjects: 17
Study: 27270177

Group type: EXPERIMENTAL
Intervention: κ.CARTs
Number of subjects: 16
Study: 27270475

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (75-g) and three isocaloric and isovolemic liquid meals with low, medium, and high fat content.
Number of subjects: 30
Study: 27270566

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flicker stimulation
Number of subjects: 18
Study: 27271157

Group type: EXPERIMENTAL
Intervention: ActiMyo® device
Number of subjects: 7
Study: 27271181

Group type: EXPERIMENTAL
Intervention: Metformin Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27271182

Group type: EXPERIMENTAL
Intervention: Day-and-Night Closed-Loop Control using the Unified Safety System
Number of subjects: 0
Study: 27271191

Group type: EXPERIMENTAL
Intervention: Offspring of women with type 1 diabetes
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control group from the background population
Number of subjects: 277
Study: 27271455

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (developmentally appropriate home safety intervention)
Number of subjects: 291
Study: 27271730

Group type: EXPERIMENTAL
Intervention: AASPIRE Healthcare toolkit including the Autism Healthcare Accommodations Tool (AHAT)
Number of subjects: 259
Study: 27272171

Group type: COMPARATOR
Intervention: ABT-494 single dose (1-48 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: ABT-494 multiple dose (3-24 mg twice daily for 14 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: ABT-494 multiple dose (3-24 mg twice daily for 27 days) in RA subjects
Number of subjects: 114
Study: 27272279

Group type: EXPERIMENTAL
Intervention: Radium-223 (IV) 50 kBq/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Radium-223 (IV) 100 kBq/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Radium-223 (IV)
Number of subjects: 6